CN116098947A - Preparation process of compound sea snake combined preparation - Google Patents
Preparation process of compound sea snake combined preparation Download PDFInfo
- Publication number
- CN116098947A CN116098947A CN202310106974.7A CN202310106974A CN116098947A CN 116098947 A CN116098947 A CN 116098947A CN 202310106974 A CN202310106974 A CN 202310106974A CN 116098947 A CN116098947 A CN 116098947A
- Authority
- CN
- China
- Prior art keywords
- sea snake
- caulis
- extract
- parts
- combination preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001136306 Hydrophiidae Species 0.000 title claims abstract description 70
- 238000002360 preparation method Methods 0.000 title claims abstract description 64
- 150000001875 compounds Chemical class 0.000 title claims abstract description 41
- 239000003094 microcapsule Substances 0.000 claims abstract description 30
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 11
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 11
- 239000009910 sargent gloryvine Substances 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 238000013268 sustained release Methods 0.000 claims abstract description 6
- 239000012730 sustained-release form Substances 0.000 claims abstract description 5
- 239000000284 extract Substances 0.000 claims description 55
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 238000003756 stirring Methods 0.000 claims description 26
- 238000002791 soaking Methods 0.000 claims description 25
- 239000002502 liposome Substances 0.000 claims description 24
- 239000000706 filtrate Substances 0.000 claims description 23
- 238000001914 filtration Methods 0.000 claims description 22
- 238000001291 vacuum drying Methods 0.000 claims description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 15
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 15
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 14
- 108010010803 Gelatin Proteins 0.000 claims description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 14
- 239000008273 gelatin Substances 0.000 claims description 14
- 229920000159 gelatin Polymers 0.000 claims description 14
- 235000019322 gelatine Nutrition 0.000 claims description 14
- 235000011852 gelatine desserts Nutrition 0.000 claims description 14
- 238000007873 sieving Methods 0.000 claims description 13
- 239000006185 dispersion Substances 0.000 claims description 12
- 239000000725 suspension Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000005520 cutting process Methods 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 229930003427 Vitamin E Natural products 0.000 claims description 7
- 235000012000 cholesterol Nutrition 0.000 claims description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 7
- 239000008055 phosphate buffer solution Substances 0.000 claims description 7
- 235000019165 vitamin E Nutrition 0.000 claims description 7
- 229940046009 vitamin E Drugs 0.000 claims description 7
- 239000011709 vitamin E Substances 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 5
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 5
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 5
- 238000007792 addition Methods 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 239000000787 lecithin Substances 0.000 claims description 5
- 235000010445 lecithin Nutrition 0.000 claims description 5
- 229940067606 lecithin Drugs 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- 230000009471 action Effects 0.000 claims description 4
- 210000002468 fat body Anatomy 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 241000282376 Panthera tigris Species 0.000 claims description 3
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000011344 liquid material Substances 0.000 claims description 2
- 229940083466 soybean lecithin Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 7
- 240000008866 Ziziphus nummularia Species 0.000 claims 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 235000006545 Ziziphus mauritiana Nutrition 0.000 abstract 1
- 244000126002 Ziziphus vulgaris Species 0.000 abstract 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 34
- 229940079593 drug Drugs 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 241000700159 Rattus Species 0.000 description 12
- 241001247821 Ziziphus Species 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 description 7
- 230000008961 swelling Effects 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 210000001503 joint Anatomy 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 102000000503 Collagen Type II Human genes 0.000 description 4
- 108010041390 Collagen Type II Proteins 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 238000005470 impregnation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 235000019633 pungent taste Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000227129 Aconitum Species 0.000 description 1
- 241000173529 Aconitum napellus Species 0.000 description 1
- 241000722953 Akebia Species 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 235000003717 Boswellia sacra Nutrition 0.000 description 1
- 240000007551 Boswellia serrata Species 0.000 description 1
- 235000012035 Boswellia serrata Nutrition 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 241000131329 Carabidae Species 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 241000258920 Chilopoda Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 240000007311 Commiphora myrrha Species 0.000 description 1
- 235000006965 Commiphora myrrha Nutrition 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000123589 Dipsacus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001506371 Kadsura Species 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 241000212322 Levisticum officinale Species 0.000 description 1
- 241000218164 Menispermaceae Species 0.000 description 1
- 241000361919 Metaphire sieboldi Species 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 241000283966 Pholidota <mammal> Species 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 241000270273 Ptyas dhumnades Species 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 241000758724 Schisandraceae Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 244000107975 Strychnos nux-vomica Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- -1 amine alkaloid Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002872 effect on rheumatism Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000001645 levisticum officinale Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/583—Snakes; Lizards, e.g. chameleons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the technical field of traditional Chinese medicines and discloses a preparation process of a compound sea snake combined preparation, which is prepared by extracting active ingredients of sea snakes, radix zanthoxyli, cassia twig, caulis sargentgloryvine stem, radix zanthoxyli and Chinese date and combining with a caulis tinosporae sustained-release microcapsule.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a preparation process of a compound sea snake combination preparation.
Background
Rheumatoid arthritis is a chronic disease which mainly shows pathological symptoms of muscles, joints, bones and cartilage tissues around bones and repeatedly attacks, is easy to cause pathological changes of body connective tissues, can even limit the actions of patients when serious, can bring great pain to the patients, and can bring great inconvenience to the daily life of the patients. At present, western medicine has no specific treatment method in the treatment of rheumatoid arthritis, mainly uses drug treatment, improves the life quality of patients by relieving symptoms and inhibiting the development of illness, but western medicine has stronger toxic and side effects, causes irrecoverable damage to liver and kidney functions of patients after long-term administration, has small toxic and side effects, has more and more research and clinical application in treating the rheumatoid arthritis in recent years, such as application of traditional Chinese medicine preparations of cassia twig, radix paeoniae alba, rhizoma anemarrhenae soup, flavored astragalus, cassia twig, schisandra chinensis soup, arthralgia healing soup and the like, and the status of the traditional Chinese medicine in the treatment field of the rheumatoid arthritis is strengthened.
The Chinese patent application No. CN201510060621.3 discloses a traditional Chinese medicine composition for treating rheumatic and rheumatoid diseases, which takes pseudo-ginseng, frankincense, myrrh, prepared nux vomica, prepared pangolin scales, angelica, szechuan lovage rhizome, common monkshood mother root, kusnezoff monkshood root, ground beetle, dahurian angelica root, safflower, akebia stem, centipede, scorpion, common dipsacus root, zaocys dhumnade, earthworm, caulis sinomenii, kadsura pepper stem and Dan Tenghe dried ginger as main components, and the components are mutually influenced to generate synergistic effect, so that the prepared traditional Chinese medicine composition has obvious curative effect on rheumatism, but after the traditional Chinese medicine composition is taken, most of the traditional Chinese medicine composition is decomposed by gastric juice, a large amount of effective components are not absorbed, so that the traditional Chinese medicine composition is discharged from the body, not only is extremely wasted, but also the taking times of patients are increased, and the economic burden on treatment is brought to the patients, therefore, a slow control system is formed, the utilization rate of the medicine is improved, the medicine taking times is reduced, and great significance is achieved.
Disclosure of Invention
The invention aims to provide a preparation process of a compound sea snake combined preparation, which is characterized in that active ingredients in the caulis tinosporae are extracted, then the active ingredients are prepared into liposome, then the liposome is compounded with gelatin to prepare a caulis tinosporae slow-release microcapsule, and then the microcapsule is combined with traditional Chinese medicine components such as sea snakes, so that the prepared compound sea snake combined preparation has good therapeutic effect on rheumatoid arthritis, and the drug utilization rate can be improved through a slow-release system, the drug administration times of patients can be reduced, and the therapeutic cost can be reduced.
The aim of the invention can be achieved by the following technical scheme:
the preparation process of the compound sea snake combination preparation comprises the following raw materials in parts by weight: 5-15 parts of sea snake, 5-10 parts of wide-tendon slow-release microcapsule, 10-15 parts of radix zanthoxyli, 5-20 parts of cassia twig, 10-20 parts of caulis sargentgloryvine, 5-10 parts of black tiger root and 5-10 parts of jujube; the wide-vine slow-release microcapsule is prepared by extracting active ingredients in wide-vine, preparing wide-vine extract liposome by an injection method, and finally adsorbing gelatin on the periphery of the liposome by electrostatic action;
the preparation process of the compound sea snake combination preparation comprises the following steps:
step one: cutting sea snake, adding into 70% ethanol for first soaking, filtering to obtain residue, collecting filtrate, continuously soaking in 70% ethanol for the second time, filtering to collect filtrate, mixing filtrates, concentrating under reduced pressure, and vacuum drying to obtain sea snake extract;
step two: pulverizing radix Zanthoxyli, ramulus Cinnamomi, caulis Sargentodoxae, radix Hedyotidis Diffusae and fructus Jujubae, sieving, soaking in 45% ethanol for 36-48 hr, percolating, collecting percolate, concentrating under reduced pressure, and vacuum drying to obtain mixed extract;
step three: mixing sea snake extract, mixed extract and caulis Sargentodoxae sustained release microcapsule, stirring, and packaging to obtain compound sea snake combined preparation.
Through the technical scheme, the sea snake is of the subfamily cobalaceae, takes meat, blood and gall as medicines, has salty taste and flat nature, has the effects of dispelling wind-dampness and strengthening bones and muscles, and is commonly used for treating wind-cold-dampness arthralgia, difficulty in flexion and extension, deficiency and other symptoms; the herba Lycopodii is rattan stem of radix Ardisiae Japonicae of Menispermaceae, has bitter taste, cool nature, and can enter liver and spleen channels, and has effects of relieving rigidity of muscles and activating collaterals, dispelling pathogenic wind and relieving pain, and its extract mainly contains quaternary amine alkaloid etc. active ingredients, and is commonly used for treating rheumatalgia, lumbar muscle strain, traumatic injury etc.; the radix zanthoxyli is a rue plant, has bitter and pungent taste, has the effects of promoting blood circulation, removing blood stasis, promoting qi circulation, relieving pain, dispelling wind, dredging collaterals, detoxifying, reducing swelling and the like, and is commonly used for treating traumatic injury, stomachache, toothache, rheumatalgia, venomous snake bite, burns and scalds and other diseases; ramulus Cinnamomi is a Lauraceae plant, has pungent and sweet taste, has strong heat property, can enter kidney and spleen channels, has effects of invigorating fire and yang, dispelling cold and relieving pain, promoting blood circulation and dredging channels, and can be used for treating symptoms such as cold arthralgia lumbago, cold hernia and running, cold coagulation and blood stasis caused by kidney yang deficiency; caulis seu radix Kadsurae Longipedunculatae is woody vine of Rhamnaceae, has light taste, mild nature, and effects of invigorating qi and blood, dispelling pathogenic wind and activating collaterals, and is commonly used for treating blood deficiency, rheumatalgia, numbness of limbs, traumatic injury, etc.; the black tiger root is a schisandraceae plant, has pungent and slightly bitter taste and warm nature, has the effects of promoting qi circulation and relieving pain, dispelling wind and activating collaterals, removing blood stasis and detumescence, and is commonly used for treating rheumatism bone pain, fatigue lumbago and other diseases; the jujube has sweet taste and warm nature, enters spleen and stomach channels, and has the effects of strengthening spleen and replenishing qi, nourishing blood and tranquillizing, nourishing liver and relieving medicine property; the compound sea snake combined preparation is prepared by taking sea snakes as monarch drugs, slow-release microcapsules of the wide-muscle vines as ministerial drugs, jujube and caulis sargentgloryvine as adjuvant drugs, radix zanthoxyli, cassia twig and radix zanthoxyli as conductant drugs, and the components of the traditional Chinese medicines are mutually cooperated and combined.
Further, in the first step, the time of the first impregnation is 10-15 days, and the time of the second impregnation is 5-7 days.
Further, in the second step, the mesh number of the sieving is 80-100 mesh.
Further, the preparation process of the wide-vine slow-release microcapsule is as follows:
s1: cleaning caulis et folium Linderae sinensis, cutting, grinding, and sieving with 50-100 mesh sieve to obtain caulis et folium Linderae sinensis powder;
s2: pouring the caulis et folium sinensis powder into purified water according to a liquid-material ratio of 1:8-10, soaking for 12-24h, transferring into an ultrasonic instrument, extracting for 2-3 times, filtering, collecting filtrate, concentrating under reduced pressure, and vacuum drying to obtain caulis et folium sinensis extract for later use;
s3: pouring the caulis tinosporae sinensis extract, the bean lecithin, the cholesterol and the vitamin E into diethyl ether, stirring to form uniform dispersion liquid, heating a phosphate buffer solution to 40-50 ℃, keeping a constant temperature state, injecting the dispersion liquid at a constant speed, stirring for 1-2h after the addition, homogenizing by using a high-pressure homogenizing machine, and preparing a fat body suspension of the caulis tinosporae sinensis extract for later use;
s4: mixing gelatin water solution with volume concentration of 10-20% with liposome suspension of herba Lycopodii extract in equal volume, adding acetic acid dropwise to adjust pH to 4, stirring for 20-40min, controlling system temperature to 0-5deg.C, adding formaldehyde, stirring for 10-20min, heating to 50-60deg.C, solidifying for 1-2 hr, cooling, filtering, and vacuum drying to obtain herba Lycopodii slow release microcapsule.
According to the technical scheme, the effective components in the caulis tinosporae sinensis are extracted through an ultrasonic auxiliary extraction method, and then the injection method is adopted to prepare the fat vine extract liposome suspension, and because the liposome is electronegative in a solution and gelatin is electropositive under an acidic condition, the fat vine extract liposome suspension can be mutually attracted through electrostatic interaction to form the fat vine liposome coated with the gelatin layer, and then the fat vine liposome is crosslinked and solidified through formaldehyde, so that the fat vine slow-release microcapsule is prepared.
Further, in the step S2, the ultrasonic frequency of the ultrasonic instrument is 60-80kHz, and the ultrasonic instrument is used for extracting for 40-60min at the temperature of 70-80 ℃.
Further, in the step S3, the mass ratio of the caulis tinosporae sinensis extract, the bean lecithin, the cholesterol and the vitamin E is 1:4-5:1.2-1.5:0.2-0.4.
Further, in the step S3, the concentration of the phosphate buffer solution is 8-10mmol/L.
Further, in step S3, the volume ratio of the phosphate buffer solution to the dispersion solution is 1:4-6.
Further, in the step S4, the volume concentration of the formaldehyde is 35-40%.
The invention has the beneficial effects that:
(1) The compound sea snake combined preparation takes sea snakes as principal drugs, the slow-release microcapsules of the caulis sinomenii as ministerial drugs, the jujubes and the caulis sargentgloryvine as adjuvant drugs, the radix zanthoxyli, the cassia twig and the radix zanthoxyli as conductant drugs, and the principal drugs, the ministerial drugs, the adjuvant drugs and the conductant drugs are mutually matched to form the drug effect complementation, so that the prepared compound sea snake combined preparation has good rheumatoid arthritis treatment effect, and meanwhile, the pure traditional Chinese medicine formula is mild and has no stimulation, compared with western medicines, the damage to liver functions is small, and no extra burden is caused to the body after long-term administration.
(2) According to the invention, the wide-vine extract liposome is prepared, and then the gelatin layer is coated on the periphery of the liposome by electrostatic adsorption, so that the wide-vine slow-release microcapsule is prepared, the wide-vine extract is difficult to contact with air, sunlight and the like through coating of the gelatin layer, the phenomenon that the medicine effect of the wide-vine extract is lost due to oxidization can be avoided, after the wide-vine slow-release microcapsule is taken, the gelatin layer can be decomposed under the action of gastric juice, the liposome is exposed, the liposome has good biocompatibility and can be adhered to the gastric wall, the medicine effect is prevented from being discharged outside the body without being absorbed, a slow-release effect is formed, the wide-vine extract liposome is transported to a focus target part through blood circulation, the wide-vine extract is released at the target part, the absorption of the wide-vine extract can be promoted by the existence of the liposome, the targeted treatment of rheumatoid arthritis can be further played, and meanwhile, the medicine utilization rate of a patient can be improved by a slow-release system.
Of course, it is not necessary for any one product to practice the invention to achieve all of the advantages set forth above at the same time.
Detailed Description
The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the embodiments, and it is apparent that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1
The preparation process of the compound sea snake combination preparation comprises the following raw materials in parts by weight: 5 parts of sea snake, 5 parts of wide-tendon slow-release microcapsules, 10 parts of radix zanthoxyli, 5 parts of cassia twig, 10 parts of caulis sargentgloryvine, 5 parts of radix zanthoxyli and 5 parts of jujube;
the preparation process of the compound sea snake combination preparation comprises the following steps:
step one: cutting sea snake, soaking in 70% ethanol for 10 days, filtering to obtain residue, collecting filtrate, soaking in 70% ethanol for 5 days, filtering to collect filtrate, mixing filtrates, concentrating under reduced pressure, and vacuum drying to obtain sea snake extract;
step two: pulverizing radix Zanthoxyli, ramulus Cinnamomi, caulis Sargentodoxae, radix Hedyotidis Diffusae and fructus Jujubae, sieving with 80 mesh sieve, soaking in 45% ethanol for 36 hr, percolating, collecting percolate, and distilling under reduced pressure to obtain mixed extract;
step three: mixing sea snake extract, mixed extract and caulis Sargentodoxae sustained release microcapsule, stirring, and packaging to obtain compound sea snake combined preparation.
The preparation process of the wide-vine slow-release microcapsule comprises the following steps of:
s1: cleaning caulis et folium Linderae sinensis, cutting, grinding, and sieving with 50 mesh sieve to obtain caulis et folium Linderae sinensis powder;
s2: pouring 1g of the caulis tinosporae sinensis powder into 10mL of purified water, soaking for 12h, transferring to an ultrasonic instrument, setting ultrasonic frequency to be 60kHz, extracting for 40min at 70 ℃ for 2 times, filtering, collecting filtrate, concentrating under reduced pressure, and vacuum drying to obtain a caulis tinosporae sinensis extract for later use;
s3: pouring 1g of the caulis tinosporae sinensis extract, 4g of bean lecithin, 1.2g of cholesterol and 0.2g of vitamin E into diethyl ether, stirring to form uniform dispersion, heating 10mL of phosphate buffer solution with the concentration of 8mmol/L to 40 ℃, keeping a constant temperature state, injecting 40mL of dispersion at a constant speed, stirring for 1h after adding, homogenizing by using a high-pressure homogenizer to prepare a fat body suspension of the caulis tinosporae sinensis extract for later use;
s4: mixing gelatin water solution with volume concentration of 10% with liposome suspension of herba Lycopodii extract in equal volume, adding acetic acid dropwise to adjust pH to 4, stirring for 20min, controlling system temperature to 0deg.C, adding formaldehyde with volume concentration of 35%, stirring for 10min, heating to 50deg.C, solidifying for 1 hr, cooling, filtering, and vacuum drying to obtain herba Lycopodii slow release microcapsule.
Example 2
The preparation process of the compound sea snake combination preparation comprises the following raw materials in parts by weight: 10 parts of sea snake, 8 parts of a wide-tendon slow-release microcapsule, 12 parts of radix zanthoxyli, 10 parts of cassia twig, 15 parts of caulis sargentgloryvine, 6 parts of radix zanthoxyli and 8 parts of jujube;
the preparation process of the compound sea snake combination preparation comprises the following steps:
step one: cutting sea snake, soaking in 70% ethanol for 15 days, filtering to obtain residue, collecting filtrate, soaking in 70% ethanol for 7 days, filtering to collect filtrate, mixing filtrates, concentrating under reduced pressure, and vacuum drying to obtain sea snake extract;
step two: pulverizing radix Zanthoxyli, ramulus Cinnamomi, caulis Sargentodoxae, radix Hedyotidis Diffusae and fructus Jujubae, sieving with 100 mesh sieve, soaking in 45% ethanol for 48 hr, percolating with percolation method, collecting percolate, concentrating under reduced pressure, and vacuum drying to obtain mixed extract;
step three: mixing sea snake extract, mixed extract and caulis Sargentodoxae sustained release microcapsule, stirring, and packaging to obtain compound sea snake combined preparation.
The preparation process of the wide-vine slow-release microcapsule comprises the following steps of:
s1: cleaning caulis et folium Linderae sinensis, cutting, grinding, and sieving with 100 mesh sieve to obtain caulis et folium Linderae sinensis powder;
s2: pouring 1g of the caulis tinosporae sinensis powder into 10mL of purified water, soaking for 18h, transferring to an ultrasonic instrument, setting the ultrasonic frequency to be 70kHz, extracting for 50min at 80 ℃ for 3 times, filtering, collecting filtrate, concentrating under reduced pressure, and vacuum drying to obtain a caulis tinosporae sinensis extract for later use;
s3: pouring 1g of the herba lycopodii extract, 4.5g of bean lecithin, 1.5g of cholesterol and 0.3g of vitamin E into diethyl ether, stirring to form uniform dispersion, heating 10mL of 10mmol/L phosphate buffer to 50 ℃, keeping a constant temperature state, injecting 50mL of dispersion at a constant speed, stirring for 2h after the addition, and homogenizing by using a high-pressure homogenizer to prepare a herba lycopodii extract liposome suspension for later use;
s4: mixing gelatin water solution with volume concentration of 15% with liposome suspension of herba Lycopodii extract in equal volume, adding acetic acid dropwise to adjust pH to 4, stirring for 30min, controlling system temperature to 5deg.C, adding formaldehyde with volume concentration of 37%, stirring for 15min, heating to 60deg.C, solidifying for 2 hr, cooling, filtering, and vacuum drying to obtain herba Lycopodii slow release microcapsule.
Example 3
The preparation process of the compound sea snake combination preparation comprises the following raw materials in parts by weight: 15 parts of sea snake, 10 parts of wide-tendon slow-release microcapsule, 15 parts of radix zanthoxyli, 20 parts of cassia twig, 20 parts of caulis sargentgloryvine, 10 parts of radix zanthoxyli and 10 parts of jujube;
the preparation process of the compound sea snake combination preparation comprises the following steps:
step one: cutting sea snake, soaking in 70% ethanol for 15 days, filtering to obtain residue, collecting filtrate, soaking in 70% ethanol for 7 days, filtering to collect filtrate, mixing filtrates, concentrating under reduced pressure, and vacuum drying to obtain sea snake concentrate;
step two: pulverizing radix Zanthoxyli, ramulus Cinnamomi, caulis Sargentodoxae, radix Hedyotidis Diffusae and fructus Jujubae, sieving with 100 mesh sieve, soaking in 45% ethanol for 48 hr, percolating with percolation method, collecting percolate, concentrating under reduced pressure, and vacuum drying to obtain mixed extract;
step three: mixing sea snake concentrated solution, mixed extract and slow-release microcapsule of caulis Sargentodoxae, stirring, and packaging to obtain compound sea snake preparation.
The preparation process of the wide-vine slow-release microcapsule comprises the following steps of:
s1: cleaning caulis et folium Linderae sinensis, cutting, grinding, and sieving with 100 mesh sieve to obtain caulis et folium Linderae sinensis powder;
s2: pouring 1g of the caulis tinosporae sinensis powder into 10mL of purified water, soaking for 24h, transferring to an ultrasonic instrument, setting ultrasonic frequency to 80kHz, extracting for 60min at 80 ℃ for 3 times, filtering, collecting filtrate, concentrating under reduced pressure, and vacuum drying to obtain a caulis tinosporae sinensis extract for later use;
s3: pouring 1g of the caulis tinosporae sinensis extract, 5g of soybean lecithin, 1.5g of cholesterol and 0.4g of vitamin E into diethyl ether, stirring to form uniform dispersion, heating 10mL of 10mmol/L phosphate buffer to 50 ℃, keeping a constant temperature state, injecting 60mL of dispersion at a constant speed, stirring for 2h after adding, homogenizing by using a high-pressure homogenizer to prepare a fat body suspension of the caulis tinosporae sinensis extract for later use;
s4: mixing gelatin water solution with volume concentration of 20% with liposome suspension of herba Lycopodii extract, adding acetic acid dropwise to adjust pH to 4, stirring for 40min, controlling system temperature to 5deg.C, adding formaldehyde with volume concentration of 40%, stirring for 20min, heating to 60deg.C, solidifying for 2 hr, cooling, filtering, and vacuum drying to obtain herba Lycopodii slow release microcapsule.
Comparative example 1
The preparation process of the compound sea snake combination preparation comprises the following raw materials in parts by weight: 10 parts of sea snake, 8 parts of caulis tinosporae sinensis, 12 parts of radix zanthoxyli, 10 parts of cassia twig, 15 parts of caulis sargentgloryvine, 6 parts of radix zanthoxyli and 8 parts of jujube;
the preparation process of the compound sea snake combination preparation comprises the following steps:
step one: cutting sea snake, soaking in 70% ethanol for 15 days, filtering to obtain residue, collecting filtrate, soaking in 70% ethanol for 7 days, filtering to collect filtrate, mixing filtrates, concentrating under reduced pressure, and vacuum drying to obtain sea snake extract;
step two: pulverizing radix Zanthoxyli, ramulus Cinnamomi, caulis Piperis Kadsurae, radix Rumicis Kadsurae, fructus Jujubae and caulis et folium Gaultheriae Yunnanensis, sieving with 100 mesh sieve, soaking in 45% ethanol for 48 hr, percolating, collecting percolate, concentrating under reduced pressure, and vacuum drying to obtain mixed extract;
step three: mixing sea snake extract and mixed extract, stirring, and packaging to obtain compound sea snake preparation.
Efficacy detection
60 female rats weighing about 50g were randomly divided into a blank experiment group, a model group, an example 1 group, an example 2 group, an example 3 group and a comparative example 1 group, each group having 10 rats; in addition, bovine type II collagen was dissolved in glacial acetic acid at a concentration of 0.01mol/L and a pH of 3.2, and fully emulsified in a temperature environment of 4℃overnight with the addition of complete Freund's adjuvant to prepare a bovine type II collagen emulsion at a concentration of 1.0mg/mL, all rats were anesthetized, 0.1mL of bovine type II collagen emulsion was injected into the ball, back and tail root of each rat in the experimental group and the model group, 0.1mL of distilled water was injected into the blank control group, and after 7 days of injection, 0.1mL of bovine type II collagen emulsion was again injected into the same location in the model group and the experimental group rats, 0.1mL of distilled water was continuously injected into the blank control group, after feeding rats under the same conditions for one week, rats in the experimental group were perfused with a compound sea snake composition formulation of 1mg/100g per day, rats in the model group and the blank control group were given physiological saline stomach at a weight of 1mL/100g, joint lesion degree of the rats was observed and recorded from the beginning of intragastric lavage 21d, and a total body inflammation index score was scored as a score of 5, a score index method was evaluated as follows:
| 0 point | No red and swelling of joints |
| 1 minute | 1 joint part reddening and/or swelling |
| 2 minutes | Redness of joints and/or swelling of joints > 1 |
| 3 minutes | Redness and/or swelling of the entire paw |
| 4 minutes | Swelling of all paw including bare joint |
Accumulating joint scores as arthritis index for each rat using analysis of variance
Up to 16 minutes, the test results are shown in the following table:
| arthritis index | |
| Example 1 group | 4.25±0.68 ▲ |
| Example 2 group | 3.96±1.05 ▲ |
| Example 3 group | 4.01±0.83 ▲ |
| Comparative example 1 group | 6.59±1.37 ▲ |
| Model group | 8.31±1.64 ▲▲ |
| Blank control group | 0.00±0.00 |
Wherein the method comprises the steps of ▲ The representation is compared to a set of models, ▲ P＜0.05； ▲▲ the representation is compared with the blank control group, ▲▲ P＜0.01。
as can be seen from the above table data, after rats are injected with the compound sea snake combination preparation prepared in the examples 1-3 of the invention, the rats show a cross-bottom arthritis index, which represents that the compound sea snake combination preparation has an obvious arthritis treatment effect, and in the compound sea snake combination preparation prepared in the comparative example 1, the bunge as ministerial drug is not coated with liposome and gelatin, so that on one hand, the curative effect is possibly reduced due to oxidation of the drug, on the other hand, the compound sea snake combination preparation also has no sustained and controlled release effect, can be discharged out of the body along with excrement, has less medicinal ingredient absorption, and therefore, the arthritis index is relatively high and the treatment effect is slightly poor.
In the description of the present specification, a description referring to terms "one embodiment," "some embodiments," "examples," "specific examples," or "some examples," etc., means that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the present invention. In this specification, schematic representations of the above terms are not necessarily directed to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, the different embodiments or examples described in this specification and the features of the different embodiments or examples may be combined and combined by those skilled in the art without contradiction.
The foregoing is merely illustrative and explanatory of the principles of the invention, as various modifications and additions may be made to the specific embodiments described, or similar thereto, by those skilled in the art, without departing from the principles of the invention or beyond the scope of the appended claims.
Claims (9)
1. The preparation process of the compound sea snake combination preparation is characterized in that the compound sea snake combination preparation comprises the following raw materials in parts by weight: 5-15 parts of sea snake, 5-10 parts of wide-tendon slow-release microcapsule, 10-15 parts of radix zanthoxyli, 5-20 parts of cassia twig, 10-20 parts of caulis sargentgloryvine, 5-10 parts of black tiger root and 5-10 parts of jujube; the wide-vine slow-release microcapsule is prepared by extracting active ingredients in wide-vine, preparing wide-vine extract liposome by an injection method, and finally adsorbing gelatin on the periphery of the liposome by electrostatic action;
the preparation process of the compound sea snake combination preparation comprises the following steps:
step one: cutting sea snake, adding into 70% ethanol for first soaking, filtering to obtain residue, collecting filtrate, continuously soaking in 70% ethanol for the second time, filtering to collect filtrate, mixing filtrates, concentrating under reduced pressure, and vacuum drying to obtain sea snake extract;
step two: pulverizing radix Zanthoxyli, ramulus Cinnamomi, caulis Sargentodoxae, radix Hedyotidis Diffusae and fructus Jujubae, sieving, soaking in 45% ethanol for 36-48 hr, percolating, collecting percolate, concentrating under reduced pressure, and vacuum drying to obtain mixed extract;
step three: mixing sea snake extract, mixed extract and caulis Sargentodoxae sustained release microcapsule, stirring, and packaging to obtain compound sea snake combined preparation.
2. The process for preparing the compound sea snake combination preparation according to claim 1, wherein in the first step, the first soaking time is 10-15 days, and the second soaking time is 5-7 days.
3. The process for preparing a compound sea snake combination preparation according to claim 1, wherein in the second step, the mesh number of the sieving is 80-100 mesh.
4. The preparation process of the compound sea snake combination preparation according to claim 1, which is characterized in that the preparation process of the wide-vine slow-release microcapsule is as follows:
s1: cleaning caulis et folium Linderae sinensis, cutting, grinding, and sieving with 50-100 mesh sieve to obtain caulis et folium Linderae sinensis powder;
s2: pouring the caulis et folium sinensis powder into purified water according to a liquid-material ratio of 1:8-10, soaking for 12-24h, transferring into an ultrasonic instrument, extracting for 2-3 times, filtering, collecting filtrate, concentrating under reduced pressure, and vacuum drying to obtain caulis et folium sinensis extract for later use;
s3: pouring the caulis tinosporae sinensis extract, the bean lecithin, the cholesterol and the vitamin E into diethyl ether, stirring to form uniform dispersion liquid, heating a phosphate buffer solution to 40-50 ℃, keeping a constant temperature state, injecting the dispersion liquid at a constant speed, stirring for 1-2h after the addition, homogenizing by using a high-pressure homogenizing machine, and preparing a fat body suspension of the caulis tinosporae sinensis extract for later use;
s4: mixing gelatin water solution with volume concentration of 10-20% with liposome suspension of herba Lycopodii extract in equal volume, adding acetic acid dropwise to adjust pH to 4, stirring for 20-40min, controlling system temperature to 0-5deg.C, adding formaldehyde, stirring for 10-20min, heating to 50-60deg.C, solidifying for 1-2 hr, cooling, filtering, and vacuum drying to obtain herba Lycopodii slow release microcapsule.
5. The process for preparing a compound sea snake combination preparation according to claim 4, wherein in the step S2, the ultrasonic frequency of the ultrasonic instrument is 60-80kHz, and the extraction is carried out for 40-60min under the temperature condition of 70-80 ℃.
6. The process for preparing a compound sea snake combination preparation according to claim 4, wherein in the step S3, the mass ratio of the caulis tinosporae extract, the soybean lecithin, the cholesterol and the vitamin E is 1:4-5:1.2-1.5:0.2-0.4.
7. The process for preparing a compound sea snake combination preparation according to claim 4, wherein in the step S3, the concentration of the phosphate buffer solution is 8-10mmol/L.
8. The process for preparing a compound sea snake combination preparation according to claim 4, wherein in the step S3, the volume ratio of the phosphate buffer solution to the dispersion solution is 1:4-6.
9. The process for preparing a compound sea snake combination preparation according to claim 4, wherein in the step S4, the formaldehyde is 35-40% in volume concentration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310106974.7A CN116098947A (en) | 2023-02-10 | 2023-02-10 | Preparation process of compound sea snake combined preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310106974.7A CN116098947A (en) | 2023-02-10 | 2023-02-10 | Preparation process of compound sea snake combined preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116098947A true CN116098947A (en) | 2023-05-12 |
Family
ID=86261324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310106974.7A Pending CN116098947A (en) | 2023-02-10 | 2023-02-10 | Preparation process of compound sea snake combined preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116098947A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103505546A (en) * | 2013-10-08 | 2014-01-15 | 广东恒诚制药有限公司 | Novel technology for preparing compound sea snake tinctures |
-
2023
- 2023-02-10 CN CN202310106974.7A patent/CN116098947A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103505546A (en) * | 2013-10-08 | 2014-01-15 | 广东恒诚制药有限公司 | Novel technology for preparing compound sea snake tinctures |
Non-Patent Citations (1)
| Title |
|---|
| 戴德银等: "中国临床药物大辞典.中药成方制剂卷：全2卷", vol. 3, 中国医药科技出版社, pages: 457 - 309 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103316146B (en) | Traditional Chinese medicinal preparation for anesthesia | |
| CN104288701A (en) | Traditional Chinese medicine composition for treating cholecystitis | |
| CN111840383A (en) | Targeted spray moxibustion composition for treating rheumatic arthritis and preparation and use methods thereof | |
| CN105727236A (en) | Powder for treating red skin disease of osphronemus goramy and preparation method thereof | |
| CN113797215B (en) | Composition containing pinoresinol and cycloolivil 9-glycoside and preparation method and application thereof | |
| CN109432269A (en) | A kind of Chinese medicine composition and preparation method, purposes | |
| CN105596861A (en) | Pill used for treating adverse reaction after CT enhancement scanning and preparation method | |
| CN116098947A (en) | Preparation process of compound sea snake combined preparation | |
| CN102258602B (en) | Chinese medicinal composition for treating rheumatism and rheumatoid and preparation method thereof | |
| CN101518579B (en) | Pressure stabilizing deoppilant and preparation process | |
| CN105031380A (en) | Drug for oral local anesthesia of pregnant woman and preparation method thereof | |
| CN111419924A (en) | A topical Chinese medicinal composition for treating various muscle and bone diseases, and its preparation device | |
| CN111358915A (en) | Traditional Chinese medicine for treating congenital muscular torticollis and preparation method thereof | |
| CN101297954B (en) | Unbilical medicament for treating cough and preparation thereof | |
| CN109821002A (en) | A kind of Chinese herbs paste suitable for cancer pain | |
| CN103977243B (en) | A kind of medicine for treating uremia refractory pruritus and preparation method thereof | |
| CN112755134B (en) | Plaster for treating hyperosteogeny and preparation method thereof | |
| CN111084842B (en) | External traditional Chinese medicine composition for treating scapulohumeral periarthritis, cervical spondylosis, lumbar disc herniation and osteoarthritis | |
| CN106166251A (en) | A kind of for Chinese medicine preparation treating asthma and preparation method thereof | |
| CN106728505A (en) | A kind of Chinese medicine composition for treating pig founder | |
| CN105412730A (en) | Medicine for treating piglet edema disease and preparation method thereof | |
| CN105106757A (en) | Fat cow syndrome treatment medicine and preparation method thereof | |
| CN105031282A (en) | Medicine used for treating infantile hip joint dropsy and preparation method thereof | |
| CN105412395A (en) | Traditional Chinese medicine composition for treating hyperostosis and preparation method thereof | |
| CN104815131A (en) | Pharmaceutical composition for treating chicken gout and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230512 |
|
| RJ01 | Rejection of invention patent application after publication |